NCT00865241View on ClinicalTrials.gov

A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 30, 2002

Primary Completion Date

November 30, 2002

Study Completion Date

November 30, 2002

Conditions
Healthy
Interventions
DRUG

Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg

A: Experimental Subjects received Alpharma formulated products under fasting conditions

DRUG

CLUCOVANCE® 5 mg/500 mg Tablets, single dose

B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions

Trial Locations (1)

58102

PRACS Institute, Ltd., Fargo

Sponsors

Lead Sponsor

Actavis Inc.
All Listed Sponsors
lead

Actavis Inc.

INDUSTRY

NCT00865241 - A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Fasting Conditions | Biotech Hunter | Biotech Hunter